Market research
HN3Q.F Nova Mentis Life Science Corp
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 793K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.63
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA66980V1067
- Market cap
- 793K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.63
About
About Nova Mentis Life Science Corp
Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is based in Vancouver, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HN3Q.F discussion.
5 years, 5 months ago
Nova Mentis Life Science Corp is currently in a long term downtrend where the price is trading 48.9% below its 200 day moving average.
From a valuation standpoint, the stock is 76.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 309.2.
Nova Mentis Life Science Corp's total revenue rose by inf% to $1K since the same quarter in the previous year.
Its net income has dropped by 61.2% to $-554K since the same quarter in the previous year.
Finally, its free cash flow grew by 36.7% to $-144K since the same quarter in the previous year.
Based on the above factors, Nova Mentis Life Science Corp gets an overall score of 3/5.